Have major oncology clinical guidelines (NCCN, ESMO, ASCO) updated recommendations based on ivermectin cancer trials?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Major oncology guideline bodies (NCCN, ESMO, ASCO) have not adopted ivermectin as a recommended cancer treatment; available sources report only early-phase trials and preclinical work, with one active clinical trial in combination with immunotherapy for metastatic triple‑negative breast cancer and no guideline updates recommending ivermectin [1] [2] [3]. Media and professional summaries emphasize limited human data and caution against use outside trials [4] [5].
1. What the guideline organizations say — none have added ivermectin
Search results and guideline pages show ongoing guideline activity across many tumor types, but there is no evidence in the provided sources that NCCN, ESMO, or ASCO have updated their clinical practice guidelines to recommend ivermectin for any cancer indication; the NCCN site lists routine guideline updates for 2025–2026 but does not mention ivermectin as a recommended agent [3] [6]. ESMO materials focus on established guideline webinars and updates with no ivermectin recommendation documented in the results [7] [8]. ASCO’s role appears in sponsoring and publishing early trial abstracts, not in issuing treatment approvals or guideline endorsements for ivermectin [2] [9].
2. The clinical evidence so far — mostly preclinical and a single small phase I/II signal
The strongest human data in available reporting are small early-phase studies and abstracts. A phase I/II trial combined oral ivermectin with the anti‑PD‑1 agent balstilimab in metastatic triple‑negative breast cancer and reported safety and “encouraging CBR” in a heavily pretreated small cohort, but accrual was limited (9 patients reported in one abstract; other reports indicate 8 patients with a single partial response), and authors called for continued investigation rather than practice change [2] [4] [10]. A literature corpus documents multiple in vitro and animal studies showing antiproliferative or immunomodulatory effects of ivermectin across tumor models [11] [12] [13] [14] [15]. Systematic reviews and commentary in oncology outlets stress that these preclinical signals have not yet translated into robust randomized controlled trial evidence [1] [16].
3. What guideline committees require before changing recommendations
Guidelines like NCCN, ESMO and ASCO typically base treatment recommendations on randomized controlled trials showing efficacy and acceptable safety, supplemented by larger phase II evidence and regulatory approvals; early phase or preclinical signals alone do not meet the threshold for guideline inclusion. The materials show active guideline revisions across many cancers but no shift toward ivermectin pending higher‑quality human data [6] [7] [17]. Available reporting notes only one active clinical program testing ivermectin in combination with immunotherapy, underscoring the limited clinical footprint required to prompt guideline change [1].
4. Media and expert reaction — caution and concern about misinformation
Multiple news and specialty outlets report growing patient interest driven by social media and anecdotes, while oncologists and press coverage warn there is “no evidence” to support ivermectin as a cancer treatment outside trials [5] [18] [19]. Analyses of internet trends found increased social media posts about ivermectin and cancer in 2025, but journalism and professional surveys overwhelmingly caution that the evidence is insufficient and that clinicians are fielding many patient questions [1] [19] [5].
5. Safety, dosing and translational gaps — why preclinical success hasn’t become practice
Researchers note that doses active in cell lines or animal models may be difficult or unsafe to reproduce in humans, and that many positive lab findings require combination strategies and careful pharmacologic work to translate into clinical benefit; examples include in vitro synergy with recombinant methioninase or checkpoint inhibitors [20] [21] [15]. Reviews and specialty articles explicitly caution against clinical adoption given limited human safety/efficacy data and the absence of regulatory approval for cancer indications [16] [22].
6. Bottom line and how clinicians and patients are responding
Guideline panels have not updated recommendations to include ivermectin; current guidance from oncologists and cancer news outlets is to consider ivermectin only within formal clinical trials and to counsel patients about the lack of proved benefit and potential risks [2] [4] [5]. For patients asking about ivermectin, sources recommend transparent discussion, documentation of any off‑label use, and referral to trials where available [9] [18].
Limitations and open questions: Available sources do not include the full internal deliberations of NCCN, ESMO or ASCO guideline committees and do not report late‑breaking randomized trial results beyond 2025; they do indicate only one active trial and no guideline endorsements for ivermectin to date [1] [2].